written on 24.04.2014

Pfizer concedes Celebrex to Actavis, Teva after 2015 patent strike-down


Pfizer has settled its patent fight with Teva Pharmaceutical Industries and Actavis, allowing both generics companies to launch Celebrex copies in December at the latest. That's 6 months after the 2014 patent expiration, but 12 months ahead of the reissued 2015 method patent.